Xintela is a biomedical company working in the fields of stem cell therapy and targeted cancer therapy, with focus on indications with a high unmet medical need.
Watch an interview with Professor Stephen Hall, principal investigator in Xintela's phase I/IIa study with XSTEM in knee ostoearthritis. Professor Hall talks about the condition, the study, and what benefit the included patients experienced from the treatment. The interview is moderated by Martin Dominique, chief analyst, Västra Hamnen Corporate Finance.
